肥胖型子宫内膜癌的发生因素

doi:10.3760/cma.j.issn.1673-422X.2015.10.020

摘要/Abstract

摘要： 大量临床研究和流行病学资料已证实肥胖与子宫内膜癌的发生、发展密切相关，其发病机制可能涉及雌激素、胰岛素、胰岛素样生长因子、瘦素、脂联素、抵抗素、炎症因子等多种肥胖相关因子。

Abstract: Large amounts of clinical studies and epidemiological data have confirmed that obesity is closely related to the development and progression of endometrial cancer. The mechanism of the endometrial cancer may be involved estrogen, insulin, insulinlike growth factor, leptin, adiponectin, resistin fat factor, inflammatory factors and so on.

Key words: Obesity, Endometrial neoplasms, Estrogens, Insulin, Adipokines

张盈,盛修贵. 肥胖型子宫内膜癌的发生因素[J]. 国际肿瘤学杂志, 2015, 42(10): 789-792.

Zhang Ying, Sheng Xiugui. The related factors of endometrial cancer induced by obesity[J]. Journal of International Oncology, 2015, 42(10): 789-792.

参考文献

［1］ Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 19992010［J］. JAMA, 2012, 307(5): 491-497. ［2］ Cheng H, Liu P, Zhang F, et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 is highly responsive to mTOR inhibition［J］. Cancer Res, 2014, 74(1): 15-23. ［3］ Mu N, Zhu Y, Wang Y, et al. Insulin resistance: a significant risk factor of endometrial cancer［J］. Gynecol Oncol, 2012, 56(125): 751-757. ［4］ Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation implications for novel treatment strategy［J］. Gynecol Oncol, 2010, 116（1）: 92-98. ［5］ Kohda M, Hoshiya H, Katoh M, et al. Frequent loss of imprinting of IGF2 and MEST in lung adernocarcinoma［J］. Mol Carcinog, 2001, 31(4): 184-191. ［6］ Hayashi K, Carpenter KD, Spencer TE. Neonatal estrogen exposure disrupts uterine development in the postnatal sheep［J］. Endocrinology, 2004, 145(7): 3247-3257. ［7］ McGrath M, Lee IM, Buring J, et al. Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk［J］. Gynecol Oncol, 2011, 120(2): 174-178. ［8］ Otvos LJr, Haspinger E, La Russa F, et al. Design and development of a peptidebased adiponectin receptor agonist for cancer treatment［J］. BMC Biotechnol, 2011, 11: 90. ［9］ Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a casecontrol study in Greece［J］. J Clin Endocrinol Metab, 2003, 88(3): 993-997. ［10］ Ashizawa N, Yahata T, Quan J, et al. Serum leptinadiponectin ratio and endometrial cancer risk in postmenopausal female subjects［J］. Gynecol Oncol, 2010, 119(1): 65-69. ［11］ Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer［J］. Buicghim Biophys Acta, 2010, 1804(3): 581-591. ［12］ Kitta Y, Takano H, Nakamura T, et al. Low adiponectin levels predict late instent restenosis after bare metal stenting in native coronary［J］. Int J Cardiol, 2008, 131(1): 78-82. ［13］ Birmingham JM, Busik JV, Hansensmith FM, et al. Novel mechanism for obesityinduced colon cancer progression［J］. Cancinogenesis, 2009, 30(4): 690-697. ［14］ Ranhouni K, Sigmund CD, Haynes WG, et al. Hypothalamic ERK mediates the anorectic and thermogenic sympathetic effects of leptin［J］. Diabetes, 2009, 58(3): 536-542. ［15］ Brown KA, McInnes KJ, Hunger NI, et al. Subcellular localization of cyclic AMPresponsive element binding proteinregulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women［J］. Cancer Res, 2009, 69(13): 5392-5399. ［16］ Luhn P, Dallal CM, Weiss JM, et al. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial［J］. Cancer Epidemiol Biomarkers Prev, 2013, 22(7): 1304-1312. ［17］刘婷婷, 张淑春, 高维萍. 血清瘦素和胰岛素生长因子Ⅱ与子宫内膜癌的相关性研究［J］. 中华妇幼临床医学杂志, 2013, 9(5): 651-652. ［18］李婷, 周奇, 王国增, 等. 抵抗素对人子宫内膜癌细胞增殖黏附及侵袭的影响［J］. 同济大学学报: 医学版, 2011, 32(5): 46-51. ［19］ Hlavna M, Kohut L, Lipkova J, et al. Relationship of resistin levels with endometrial cancer risk［J］. Neoplasma, 2011, 58(2): 124-128. ［20］ Lee JH, Bullen JW Jr, Stoyneva VL, et al. Circulating resistin in lean, obese, and insulin resistant mouse models: lack of association with insulinemia and glycemia［J］. Am J Physiol Endocrinol Metab, 2005, 288(3): E625-E632. ［21］ Malo E, Ukkola O, Jokela M, et al. Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish Health 2000 survey［J］. Metab Syndr Relat Disord, 2011, 9(3): 203-210. ［22］ Colotta F, Allavena P, Sica A, et al. Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability［J］. Carcinogenesis, 2009, 30(7): 1073-1081. ［23］ Clendenen TV, Koenig KL, Arslan AA, et al. Factors associated with inflammation markers, a crosssectional analysis［J］. Cytokine, 2011, 56(3): 769-778.

[1]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[2]	凡梦思, 陆雅萍, 闫莉. 子宫内膜癌前哨淋巴结假阴性患者的临床病理特征分析[J]. 国际肿瘤学杂志, 2023, 50(5): 274-279.
[3]	杨洪娟, 孙云川, 何新颖, 毕建强, 肖丽. 子宫内膜中肾样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(4): 255-256.
[4]	吕璐, 孙鹏飞, 崔腾璐. 子宫内膜癌颈部淋巴结转移综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(11): 701-704.
[5]	李宁, 张玢琪. 免疫检查点抑制剂在子宫内膜癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(2): 125-128.
[6]	柳灿烔, 黄欣仪, 陈柳伊, 陈浩, 彭裕辉, 黄旭纯. 胃癌患者血清胰岛素样生长因子结合蛋白7的水平及其诊断价值[J]. 国际肿瘤学杂志, 2022, 49(12): 724-728.
[7]	鲁历历, 孙鹏飞, 叶斌强. 放化疗联合盐酸安罗替尼治疗复发性子宫内膜癌1例[J]. 国际肿瘤学杂志, 2022, 49(12): 766-768.
[8]	徐秋月, 马咸梅, 岳琦. 基于分子分型的子宫内膜癌免疫治疗[J]. 国际肿瘤学杂志, 2022, 49(11): 700-704.
[9]	邓波儿, 孔为民. 子宫内膜癌的表观遗传学研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 184-188.
[10]	何哲锋, 裴铁民, 孟庆辉. IGF2BP1与肿瘤[J]. 国际肿瘤学杂志, 2021, 48(2): 92-95.
[11]	黄于庭, 汪超. 盐酸小檗碱联合表柔比星、顺铂对晚期子宫内膜癌的抗肿瘤效果[J]. 国际肿瘤学杂志, 2020, 47(9): 530-534.
[12]	王雪, 纪国欣, 纪超, 杨兴升. 二甲双胍对合并2型糖尿病的Ⅰ型子宫内膜癌患者预后的影响[J]. 国际肿瘤学杂志, 2020, 47(7): 404-408.
[13]	赵小玲, 孔为民. 二甲双胍在子宫内膜癌中的基础与临床研究现状[J]. 国际肿瘤学杂志, 2020, 47(7): 440-443.
[14]	周露秋, 刘先喜, 李艳, 毛熙光. Ⅰ型子宫内膜癌的预后危险因素分析[J]. 国际肿瘤学杂志, 2020, 47(6): 346-350.
[15]	罗春翠, 袁超燕, 陈庆芬. GOLPH3通过PI3K/AKT/GSK3β信号调控子宫内膜癌细胞的增殖与凋亡[J]. 国际肿瘤学杂志, 2020, 47(2): 65-69.